Clazakizumab
Clazakizumab (pronounced kla-zuh-ki-zoo-mab) is a monoclonal antibody designed for the treatment of rheumatoid arthritis and psoriatic arthritis. It is currently under investigation for its potential use in other autoimmune diseases.
Etymology
The name "Clazakizumab" is derived from the International Nonproprietary Names (INN), where "claza-" is a prefix used for humanized antibodies, "-kiz-" indicates the target (interleukin 6), and "-mab" is a suffix for monoclonal antibodies.
Pharmacology
Clazakizumab works by binding to the interleukin 6 (IL-6) cytokine, a protein that plays a key role in the inflammatory response of the immune system. By blocking IL-6, Clazakizumab can help reduce inflammation and slow the progression of autoimmune diseases.
Clinical Trials
Clazakizumab has undergone Phase II clinical trials for the treatment of rheumatoid arthritis and psoriatic arthritis. The results showed a significant reduction in disease activity and improved physical function in patients treated with Clazakizumab.
Related Terms
- Monoclonal Antibody
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Autoimmune Diseases
- Interleukin 6
- Cytokine
- Inflammation
- Clinical Trials
External links
- Medical encyclopedia article on Clazakizumab
- Wikipedia's article - Clazakizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski